The test examines key variants including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313each influencing appetite regulation, metabolic rate, and medication responsiveness
Key changes that can occur after stopping include: Blood Sugar Control: For those with type 2 diabetes, stopping a GLP-1 agonist may lead to worsening glycemic control, requiring alternative medications or insulin therapy
Drinking alcohol while using GLP-1 therapy isnt off the table, but keeping it in check is very important
That is very different from saying that informal microdosing has been proven to protect the brain
Clinician oversight matters Retatrutide is investigational
Companies known to have submitted applications include established generic manufacturers such as Sandoz, Aspen Pharmacare, and Canadian company Vimy Pharma